Status:
ACTIVE_NOT_RECRUITING
Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Conditions:
Hyperlipidemias
Hypertension
Eligibility:
All Genders
19+ years
Brief Summary
The purpose of this study is to evaluate the effectiveness of Olostar Tablet on blood pressure and lipid profiles, obtain safety-related information for subgroups that failed to participate in the cli...
Eligibility Criteria
Inclusion
- men and women over the age of 19
- Patients who signed a written consent form to participate in the study
- Patients who are eligible for Olostar tablet prescription according to domestic permission
Exclusion
- A person who falls under "2. Do not administer to the following patients" among the precautions for use in the user manual
- Patients in hospital (hospitals only; nursing care facilities can be recruited)
- A person who has been administered the study target drug or is being administered at the time of recruitment within 6 months based on the date of the study contract
Key Trial Info
Start Date :
June 20 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
2845 Patients enrolled
Trial Details
Trial ID
NCT05411887
Start Date
June 20 2022
End Date
December 31 2025
Last Update
August 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Severance Hospital
Seoul, South Korea